Navigation Links
Reportlinker Adds Virtual Pharma

NEW YORK, Nov. 3, 2010 /PRNewswire/ -- announces that a new market research report is available in its catalogue:

Virtual Pharma

Systems Biology in Biotech and PharmaA new paradigm for innovationGrowth in the pharmaceutical market has slowed – almost to a standstill. One reason is that governments and other payers are cutting costs in a faltering world economy.

But a more fundamental problem is the failure of major companies to discover, develop and market new drugs. Major drugs losing patent protection or being withdrawn from the market are simply not being replaced by new therapies – the pharmaceutical market model is no longer functioning effectively and most pharmaceutical companies are failing to produce the innovation needed for success.

This new report looks at a vital strategy which can bring innovation to a market in need of new ideas and new products - Systems Biology.

Systems Biology employs a rational approach, via a mix of analytical and systemic routes, to delineate the emerging properties of biological networks. It aims to explain and predict, quantitatively, molecular, cellular, tissue, organ and whole-body processes. By using multi-scale models in silico, Systems Biology is expected to bring numerous benefits to pharmaceutical discovery and development as the properties of a system can be studied over a wide range of length and time scales.

Systems Biology can reduce the number of compounds that need to be synthesised in discovery by using refined algorithms to weed out compounds with poor pharmacokinetic of toxicology profiles. And it will save time and money by selecting the drugs which are more likely to succeed in clinical development.

This new 200 page report is written by industry and academic expert Dr Ales Prokop, one of the leading researchers in Systems Biology. It will enable you to:

  • Understand the nature and processes involved in Systems Biology
  • See how its benefits relate to pharmaceutical innovation
  • Delineate the costs and cost savings involved
  • Understand why Systems Biology improves on current approaches to drug discovery
  • Relate Systems Biology to advances in genetic profiling and personalised medicine

  • Contents include:

  • Tools and lead optimisation
  • Virtual chemistry screening
  • Lead discovery and molecular interactions
  • In silico screening
  • Computational Systems Biology in cell biology
  • Pharmacology and pharmacokinetics
  • Formulation and production
  • Model-based drug development

  • Systems Biology is essential reading for corporate management and those in product, process and analytical discovery and development, product quality and characterisation, R&D, and regulatory affairs. It is aimed at biotech, big pharma, producers of biosimilars, contract manufacturers, providers of analytical services, and clinical research organizations. This report gives an authoritative, detailed and clear explanation of the issues surrounding Systems Biology, its implications for the market and for the biotech and pharmaceutical industries.

    Table of Contents Systems Biology in Biotech & Pharma: A Changing Paradigm Executive Summary

    Chapter 1 – Discovery: New Developments, Tools & Lead Optimization



    Scope & Content of the Report

    Drug Discovery & Development

    Defining SB: Key Components

    Brief History of Systems Biology (SB) in Terms of Key Advances

    Potential Impact of Systems Biology on Pharma R&D and Cost Savings

    Overall Conclusions

    Chapter 2 – Discovery: Towards Virtual Chemistry Screening



    Identifying Targets & Druggability Space

    Combinatorial Chemistry Tools

    Diversity Tools

    Diversity-Oriented Synthesis & Discovery

    Differentially Expressed Proteins

    Phage Display

    Chirality Tools

    Homology Tools at Discovery

    Homology Modeling


    Fragment Based DD

    Qualitative and Quantitative Screens & Filters

    Structure-Activity Methods (SAR/QSAR)

    Summary on Chemistry Tools at Drug Discovery: Key Findings & Opportunities

    Overall Conclusions

    Chapter 3 – Biochemistry: Phase 1 Lead Discovery & Molecular Interactions



    Molecular Screens: Receptor-Liganed (R-L) Interaction & Molecular Modeling

    Molecular Modeling

    Quantum Chemistry

    Molecular Mechanics

    Molecular Dynamics

    Receptor Based QSAR Methods

    Biomimetics (BioMim)

    Collateral Efficacy & Permissive Antagonism

    Co-Drugging: Multiple Targets, Combination Therapy & Multi-Stage Targeting

    Multi-Component Drugs

    Multi-Target Approach

    Multi-Stage Targeting

    Text Mining For Interactions

    Employment of Biochemical Networks

    Overview of Deterministic Models




    Summary on Biochemical Tools: Key Findings & Opportunities


    Chapter 4 – Molecular Biology: Phase 2 Lead Discovery & In Silico Screening






    Metabolic Profiling


    Proteome Analysis



    Minimal Phenotype & Synthetic Biology

    Reconstructing Biological Networks

    Summary on Molecular Biology Tools: Key Findings & Opportunities

    Overall Conclusions

    Chapter 5 – Discovery: Computational Systems Biology in Cell Biology


    Cellular Environment: Network Reconstruction & Inference From Experimental Data

    Reconstructing Gene Networks

    Data Mining

    Analysis of Disease Correlation Network™ & Concerted Metabolic Activation

    Challenges For Stem Cells: Control

    Emergent Properties

    Computational Systems Biology

    Summary on Quantitative CSB Tools: Key Findings & Opportunities

    Overall Conclusions

    Chapter 6 – Development: Pharmacology & Pharmacokinetics



    In Vivo Pharmacology

    Animal Disease Models

    Gene Knockout Animal Models

    Pheno- & Genotyping

    RNA Interference


    In Silico Pharmacology: Future

    Summary on In Vivo Pharmacology: Key Findings & Opportunities


    Chapter 7 – Development: Pharmacokinetics

    Summary on PK Quantitative Simulation Tools: Key Findings & Opportunities



    Towards In Silico Systems, PK & Toxicology

    Microdosing in PK

    Adaptive Trial Design

    Equilibrium vs. Non-Equilibrium PK Models

    Toxicity Biomarkers

    In Silico Toxicity Prediction

    Quantitative PK-PD/Tox Modeling


    Chapter 8 – Development: Multiscale CSB



    Redefining (& Discovering) Emergent Properties at Higher-Level Hierarchies

    Virtual Organs, Disease Models, Virtual Patient

    Population Level Model: Towards Individualized Medicine

    Targeting Networks: Towards Organisimc & Full-Scale Quantitative Design

    Redefining the Traditional R&D Paradigm

    Summary of Multiscale CSB: Key Findings & Opportunities


    Chapter 9: Development: Drug Formulation & Manufacturing



    Drug Formulation & Delivery

    Targeting Concept & Mechanisms

    Nanoscale Drug Delivery Systems

    CSB at Formulation & Delivery

    Summary of Drug Formulation: Key Finding & Opportunities


    Process Design & Production



    Metabolic Engineering

    Parallel Cultivation Methods for Bioprocessing

    Bioprocess & Equipment Scale-Up

    Qualitative Systems Tools

    Rule of Thumb

    Towards Quantitative Production Design

    Summary on Design & Production: Key Findings & Opportunities


    Chapter 10: Development: Preclinical Model Based Drug Development



    Summary of the Clinical Model: Key Findings & Opportunities


    Chapter 11: Systems Biology: Impact on Pharma



    R&D Strategies & Investment

    Blockbuster vs. Niche Model

    Pharma vs. Biotech Model

    Outsourcing & In-Licensing

    Life Cycle Management Growth

    Diversification Growth

    Franchise Development Growth

    New Market Entry Growth

    Alliances & Collaborations: Key Players

    Bibliography & Endnote

    Regulation & Intellectual Property

    Global Regulation: Critical Path Initative (FDA)

    Intellectual Property (IP)

    Summary on R&D Strategies & Investment, Alliances & Collaborators and Regulation & Intellectual Property

    Chapter 12: Report Conclusions


    Report Conclusions

    Report Summary & Suggestions

    Key Technologies & Tools Needed for Development of Systems Biology/CSB

    Steps in Systems Biology/CSB

    Benefits of Systems Biology & CSB


    To order this report:Pharmaceutical Industry: Virtual Pharma

    Pharmaceutical Business News

    More  Market Research Report

    Check our  Company Profile, SWOT and Revenue Analysis!CONTACT:  Nicolas BombourgReportlinkerEmail: nbo@reportlinker.comUS: (805)652-2626Intl: +1 805-652-2626

    SOURCE Reportlinker
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Reportlinker Adds Quality for Biologics
    2. Reportlinker Adds Endoscopy Devices Market Outlook in Belgium to 2016 - Endoscopy Visualization Systems, Flexible and Rigid Endoscopes, Capsule Endoscope Systems and Others
    3. Reportlinker Adds Japanese Market for Urological Devices 2010
    4. Reportlinker Adds U.S. Market for Medical Imaging Equipment 2010
    5. Reportlinker Adds Indian Bulk Drug Market
    6. Reportlinker Adds Nutraceutical Market
    7. Reportlinker Adds Commercializing Cancer Vaccines: A Decision Support Tool for Optimizing the Pipeline
    8. Reportlinker Adds Global Top 10 Health Care Equipment Companies - Industry, Financial and SWOT Analysis
    9. Reportlinker Adds The Top 10 Companies in the Hospital Pharmaceutical Market in China: Growth strategies, performance and SWOT analyses
    10. Reportlinker Adds Lung Cancer Drug Futures
    11. Reportlinker Adds Prostate Cancer Drug Futures
    Post Your Comments:
    (Date:10/12/2017)... DIEGO , Oct. 12, 2017 AVACEN ... recognized the company with their  2017 New Product Innovation Award ... based on extensive primary and secondary medical device market research ... Medical, through its first-to-market OTC, drug-free pain relief product, the ... unique approach to treating fibromyalgia widespread pain. ...
    (Date:10/11/2017)... Texas , Oct. 11, 2017  True ... services, has amplified its effort during National Breast ... about hereditary cancer risks. ... of Clinical Oncology calculated that more than 10 ... have inherited mutations in BRCA1 or BRCA2 and have ...
    (Date:10/5/2017)... Ill. , Oct. 5, 2017  In ... Association of Oral and Maxillofacial Surgeons (AAOMS) released ... opioids – to be used as a first-line ... pain. Recognizing ... the AAOMS White Paper "Opioid Prescribing: Acute and ...
    Breaking Medicine Technology:
    (Date:10/13/2017)... N.J. (PRWEB) , ... October 13, 2017 , ... The ... Holly Day Market. Featuring a collection of specialty vendors and unique items from across ... personalized and quality-focused health and wellness services offered by the VNA. The boutique ...
    (Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... DevOps and Agile Software Development, has been awarded a contract by the Center ... Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies in ...
    (Date:10/12/2017)... Orleans, LA (PRWEB) , ... October 12, 2017 , ... ... centers in the U.S., announced today its plans to open a flagship location in ... will occupy the former Rooms To Go store next to Office Depot in the ...
    (Date:10/12/2017)... ... 12, 2017 , ... Information about the technology: , Otomagnetics ... enable prevention of a major side effect of chemotherapy in children. Cisplatin and ... For cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. ...
    (Date:10/12/2017)... ... October 12, 2017 , ... Women-owned ... Michigan’s 2017 Best and Brightest in Wellness® by Best and Brightest. OnSite Wellness ... on Friday, Oct. 20 from 7:30 a.m. to 2 p.m. at the Henry ...
    Breaking Medicine News(10 mins):